In a new study from the University of Arizona, researchers found that the Pfizer-BioNTech COVID-19 vaccine is a moderately effective tool for preventing the spread of COVID-19 and reducing the severity in children and adolescents.
A total of 1,364 children ages 5-15 were tested for SARS-CoV-2, the virus that causes COVID-19, weekly from July 25, 2021, to Feb. 12, 2022.
The team found that vaccination with two doses of the Pfizer-BioNTech COVID-19 vaccine reduced the risk of infection with the omicron variant by 31% in children ages 5-11 and by 59% in adolescents ages 12-15.
The report showed declining protection in adolescents when comparing the omicron and delta periods, as vaccination was 87% effective at preventing infections among adolescents ages 12-15 years when the delta variant was the dominant strain circulating in the U.S.
The Pfizer-BioNTech mRNA COVID-19 vaccine was recommended by CDC’s Advisory Committee on Immunization Practices for adolescents ages 12-15 on May 12, 2021, and children ages 5-11 years on Nov. 2, 2021.
Researchers say the findings, provide some evidence that all children and adolescents should remain up to date with recommended COVID-19 vaccinations.
The ongoing PROTECT study is among the largest studies with routine weekly COVID-19 testing, regardless of COVID-19-like symptoms.
The study monitors SARS-CoV-2 infections among participants aged 6 months to 17 years in jurisdictions in four states: Arizona, Florida, Texas and Utah.
Researchers also evaluated the severity of COVID-19 illness among unvaccinated children and adolescents who were infected during periods of delta and omicron circulation.
They found that omicron infections were less severe than delta infections.
Among unvaccinated children who were infected, children with omicron infections were less likely to report COVID-19 symptoms (49%) than children with delta infections (66%).
Symptomatic omicron infection among children and adolescents—both vaccinated and unvaccinated—resulted in an average of 5-6 days of symptoms and 1-2 days in bed.
The data also allowed researchers to gain a better understanding the factors that can affect infection risk within this age group, including socio-demographic characteristics, health information, frequency of close social contact, mask use, location and local virus circulation.
If you care about Covid, please read studies about new antiviral drug combo highly effective against COVID-19, and COVID-19 infection may boost your antibodies for up to 20 months.
For more information about Covid, please see recent studies that two doses of COVID-19 vaccine may protect against long COVID, and results showing COVID-19 virus may cause testicular damage.
The study is published in Morbidity and Mortality Weekly Report and was conducted by Karen Lutrick et al.
Copyright © 2022 Knowridge Science Report. All rights reserved.
